Component
Human clamp-measured insulin sensitivity after resveratrol
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In a randomized 24-man obesity trial, 1,500 mg/day resveratrol for four weeks did not improve clamp-measured insulin sensitivity, glucose turnover, ectopic fat or the measured metabolic/inflammatory outcomes.
Experimental context and source evidence
- evidence_access
- Primary full text
- experimental_model
- Parallel placebo-controlled trial in otherwise healthy obese men.
- limitations
- Different dose, design and endpoints from the 11-person crossover; difference alone is not a scientific contradiction.
- nutrient_topic
- Resveratrol collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Resveratrol
- plain_language
- A larger dose did not reproduce a universal metabolic benefit.
- primary_references
- High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23193181/ · DOI 10.2337/db12-0975
Resveratrol: metabolites, target selectivity and cross-nutrient mechanisms (2026-09-19) · lines 462–468
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Parallel placebo-controlled trial in otherwise healthy obese men. · source_derived_draft · unverified_draft
## resveratrol-human-metabolic-null A larger dose did not reproduce a universal metabolic benefit. In a randomized 24-man obesity trial, 1,500 mg/day resveratrol for four weeks did not improve clamp-measured insulin sensitivity, glucose turnover, ectopic fat or the measured metabolic/inflammatory outcomes. Model: Parallel placebo-controlled trial in otherwise healthy obese men. Limitations: Different dose, design and endpoints from the 11-person crossover; difference alone is not a scientific contradiction. Evidence access: Primary full text High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23193181/ · DOI 10.2337/db12-0975
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.